Kathy Dent
Impact in
- Infectious Diseases top 1%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Neurology top 5%
- Long-Term Effects of COVID-19
Papers in
-
- SARS-CoV-2 and COVID-19 Research 5
- COVID-19 Clinical Research Studies 3
-
- interferon and immune responses 3
Kathy Dent
13 papers receiving 2.7k citations
Kathy Dent's Hit Papers
Peers
Comparison fields: 5 of 121
- Infectious Diseases 1.4k
- Neurology 447
- Applied Microbiology and Biotechnology 51
- Internal Medicine 60
- Immunology 324
Countries citing papers authored by Kathy Dent
This map shows the geographic impact of Kathy Dent's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathy Dent with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathy Dent more than expected).
Fields of papers citing papers by Kathy Dent
This network shows the impact of papers produced by Kathy Dent. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathy Dent. The network helps show where Kathy Dent may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Mapping the human genetic architecture of COVID-19 Hit paper breakdown → | 2021 | 641 |
| 2 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 403 |
| 3 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 381 |
| 4 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 5 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 230 |
| 6 | Whole-genome sequencing reveals host factors underlying critical COVID-19 Hit paper breakdown → | 2022 | 228 |
| 7 | Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 211 |
| 8 | GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 Hit paper breakdown → | 2023 | 121 |
| 9 | 2017 | 108 | |
| 10 | 2023 | 83 | |
| 11 | 2023 | 56 | |
| 12 | 2019 | 19 | |
| 13 | 2024 | 8 |
About Kathy Dent
Kathy Dent is a scholar working on Infectious Diseases, Immunology, Emergency Medical Services, Genetics and Epidemiology, having authored 13 papers that have together received 2.8k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (5 papers), COVID-19 Clinical Research Studies (3 papers), interferon and immune responses (3 papers), Pneumonia and Respiratory Infections (1 paper), Patient Safety and Medication Errors (1 paper), Global Health and Surgery (1 paper), Diabetes and associated disorders (1 paper) and Respiratory viral infections research (1 paper). The work is most often cited by research in Infectious Diseases (1.4k citations), Neurology (447 citations), Applied Microbiology and Biotechnology (51 citations), Internal Medicine (60 citations) and Immunology (324 citations). Kathy Dent has collaborated with scholars based in United Kingdom, Australia and Indonesia. Their work appears in journals such as The Lancet, Nature, British Journal of Anaesthesia, Human Genetics and Genomics Advances and British journal of surgery.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.